Connect with us

Published

on

Signage at 23andMe headquarters in Sunnyvale, California, U.S., on Wednesday, Jan. 27, 2021.

David Paul Morris | Bloomberg | Getty Images

23andMe CEO Anne Wojcicki is considering a proposal to take the genetic testing company private after its stock price has tumbled more than 95% from its 2021 highs.

Wojcicki is working with advisors and plans to begin speaking to possible financing sources and partners, according to a filing with the U.S. Securities and Exchange Commission late Wednesday. She “wishes to maintain control” of the company and will “not be willing to support any alternative transaction,” the filing said.

The former billionaire co-founded 23andMe in 2006, and the company rocketed into the mainstream because of its at-home DNA testing kits that give customers insights into their family histories and genetic profiles. 23andMe went public in 2021 via a merger with a special purpose acquisition company, which valued the company at around $3.5 billion.

But despite launching two new businesses, 23andMe has struggled to generate steady recurring revenue since consumers only needed to take its DNA test once to get their results. The stock is trading around 45 cents per share Thursday morning.

In November, 23andMe received a deficiency letter from the Nasdaq Listing Qualifications Department giving it 180 days to bring its share price back above $1. The company’s board of directors formed a “Special Committee” in late March to help explore options that could juice the stock.

The committee said it has been made aware of Wojcicki’s interest in acquiring all of 23andMe’s outstanding shares, according to a release Thursday. She currently owns shares that make up more than 20% of those outstanding, which equates to around 49% of voting power, the release said.

“The Special Committee will carefully review Ms. Wojcicki’s proposal when and if it is made available and evaluate it in light of other available strategic alternatives, including continuing to operate as a publicly traded company,” the committee said in the release. “The Special Committee is committed to acting in the best interests of 23andMe and its shareholders.”

The committee has engaged Wells Fargo as its financial advisor, and it said there is “no assurance” that Wojcicki’s offer would result in the proposed outcome.

23andMe declined to comment beyond the release.

Continue Reading

Technology

UnitedHealth CEO estimates one-third of Americans could be impacted by Change Healthcare cyberattack

Published

on

By

UnitedHealth CEO estimates one-third of Americans could be impacted by Change Healthcare cyberattack

Omar Marques | Lightrocket | Getty Images

UnitedHealth Group CEO Andrew Witty on Wednesday told lawmakers that data from an estimated one-third of Americans could have been compromised in the cyberattack on its subsidiary Change Healthcare, and that the company paid a $22 million ransom to hackers.

Witty testified in front of the Subcommittee on Oversight and Investigations, which falls under the House of Representatives’ Committee on Energy and Commerce. He said the investigation into the breach is still ongoing, so the exact number of people affected remains unknown. The one-third figure is a rough estimate.

UnitedHealth has previously said the cyberattack likely impacts a “substantial proportion of people in America,” according to an April release. The company confirmed that files containing protected health information and personally identifiable information were compromised in the breach. 

It will likely be months before UnitedHealth is able to notify individuals, given the “complexity of the data review,” the release said. The company is offering free access to identity theft protection and credit monitoring for individuals concerned about their data.

Witty also testified in front of the U.S. Senate Committee on Finance on Wednesday, when he confirmed for the first time that the company paid a $22 million ransom to the hackers that breached Change Healthcare. At the hearing before the House legislators later that afternoon, Witty said the payment was made in bitcoin.

UnitedHealth disclosed that a cyberthreat actor breached part of Change Healthcare’s information technology network late in February. The company disconnected the affected systems when the threat was detected, and the disruption has caused widespread fallout across the U.S. health-care sector.

Witty told the subcommittee in his written testimony that the cyberattackers used “compromised credentials” to infiltrate Change Healthcare’s systems on Feb. 12 and deployed a ransomware that encrypted the network nine days later.

The portal that the bad actors initially accessed was not protected by multifactor authentication, or MFA, which requires users to verify their identities in at least two different ways. 

Witty told both committees Wednesday that UnitedHealth now has MFA in place across all external-facing systems.

Don’t miss these exclusives from CNBC PRO

Continue Reading

Technology

Masimo’s billionaire CEO put shares on margin to get cash while keeping ownership ahead of proxy fight

Published

on

By

Masimo's billionaire CEO put shares on margin to get cash while keeping ownership ahead of proxy fight

Founder and CEO of Masimo, Joe Kiani addresses a press conference in Bangalore on January 2, 2017. 

Manjunath Kiran | Afp | Getty Images

Billionaire Masimo founder Joe Kiani, best known for his successful legal fight against Apple and his friendship with President Joe Biden, has borrowed against half of his $660 million stake in the health-technology company rather than sell his stock, according to corporate filings from earlier this week.

Borrowing against that much of a stake is unusual for executives, but may be helpful as the company prepares for a fight with an activist aiming to take control of the board. The move allows Kiani, the company’s CEO and chairman, to maintain his stake and voting power while also getting money he says he needs for family reasons.

Many medical-tech peers bar such moves, and it could leave Kiani susceptible to margin calls if Masimo’s stock falls below a certain threshold. Kiani has just under 4 million Masimo shares, or around 7.5% of the company, according to FactSet data.

Masimo, which makes wearables and health monitoring products, is preparing to fend off a second proxy fight waged by Quentin Koffey’s Politan Capital Management. Kiani described Koffey as “destructive” in a March CNBC interview.

Masimo shares are up 15% this year, lifting the company’s market cap past $7 billion. The stock had a volatile run in the back half of 2023, falling 47% in the third quarter before gaining 34% in the fourth.

Politan controls 8.9% of Masimo shares. While that’s bigger than Kiani’s stake, even before pledged shares are weighed, regulatory filings show that the CEO has options that could boost his holdings to 9.2% if exercised.

Politan already won two seats on Masimo’s six-person board in a contentious 2023 proxy fight, but announced last month that it would seek two more seats, including Kiani’s, to cement control.

Kiani, 59, pledged 2.97 million Masimo shares as of April, valued at $397 million, as collateral against “personal loans.” The company said in its annual filing Kiani had family “financial planning objectives” that would require him to sell his stock, but that he “did not want to diminish his shareholdings.” His objectives weren’t spelled out in the filings.

“The pledge of shares was pre-approved by the Board and reflects Mr. Kiani’s conviction in the value of Masimo stock despite the short-term decline in the stock price during the second half of 2023,” a Masimo spokesman said in an emailed statement. “Rather than sell his pledged shares, Mr. Kiani increased his pledge to maintain his stock ownership.”

The spokesperson added that Kiani purchased about $7 million worth of Masimo stock in the second half of 2022 and the first half of 2023.

The Masimo logo is displayed at Masimo headquarters on December 27, 2023 in Irvine, California. 

Mario Tama | Getty Images

Kiani is a major Democratic donor who is reportedly close with President Biden. He also has an 8,000-acre winery in Santa Ynez, California, near Santa Barbara.  The lending is an increase from the year before, when Kiani only pledged 400,000 shares as collateral.

Masimo’s board also includes Bob Chapek, who joined in January, almost exactly a year after was he ousted as Disney’s CEO.

Several of Masimo’s peers, like Agilent, Stryker and Medtronic, don’t allow executives to pledge their shares. Companies generally frown upon stock pledging, though some, including Masimo, permit it with board approval. Stock-backed lending, or “Lombard loans,” generally requires a borrower to sell their shares if they fall below a certain value, which in the case of large shareholders can drive a stock price down even further.

Masimo’s earlier proxy fight was marked by litigation between the two sides that led to Politan winning $18 million in legal fees after forcing the company to abandon an effort to thwart the investment firm. There were also personal attacks. In regulatory filings, the company described Koffey as someone with “hubris” that was “no different than his more prominent peer Bill Ackman.”

Major shareholders, including Vanguard, sided with the activist, which said that Masimo had been marred by poor governance practices and the acquisition of Sound United, a consumer audio company. Masimo shares plummeted 37% the day the deal was announced in February 2022.

Last month, Masimo said it would spin off its consumer business, an announcement that boosted the stock. When Politan announced its second campaign days later, shares rose even higher. Politan has said news of the spinoff, made after the bell on a Friday and shortly before the activist announced its second campaign, was “rushed” when the company learned of the activist’s plans.

Masimo has denied that claim. The company has yet to file a proxy statement or schedule an annual meeting.

Masimo has had some success in recent months. The company pursued high-profile patent litigation against Apple, alleging that the company infringed on its pulse oximeter technology for the Apple Watch. After some initial setbacks, Masimo won a ruling that restricted the sale of some watches. The two companies remain in negotiations on the matter.

WATCH: Masimo CEO Joe Kiani on consumer spinoff and proxy fight

Masimo CEO on potential split, proxy battle and spinning off consumer business

Continue Reading

Technology

Qualcomm gives better-than-expected revenue forecast as company pushes AI-powered smartphones

Published

on

By

Qualcomm gives better-than-expected revenue forecast as company pushes AI-powered smartphones

Qualcomm CEO Cristiano Amon responds to a question during a keynote conversation at CES 2024, an annual consumer electronics trade show, in Las Vegas, Nevada, on Jan. 10, 2024.

Steve Marcus | Reuters

Qualcomm reported second-quarter earnings on Wednesday that surpassed Wall Street expectations, and provided a strong guide for the current quarter.

Shares rose about 4% in extended trading.

Here’s how it did versus LSEG consensus estimates for the quarter ended March 24:

  • Earnings per share: $2.44 adjusted vs. $2.32 expected
  • Revenue: $9.39 billion adjusted vs. $9.34 billion expected

Net income during the quarter was $2.33 billion, or $2.06 per share, versus $1.7 billion, or $1.52 per share, in the year-earlier period.

Qualcomm said it expected between $8.8 billion and $9.6 billion in sales in the current quarter, higher than Wall Street expectations of $9.05 billion. Analysts were looking for earnings guidance of $2.17 per share, versus the company’s forecast of between $2.15 and $2.35.

Qualcomm said on the earnings call that it expected overall handset revenues to decline during the current quarter by “mid-single digit percent” because of a lack of summer smartphone launches, which is a typical seasonal pattern.

Qualcomm’s most important business is its handsets business. It sells processors, modems and other parts for smartphones — primarily Android devices, but also some modem parts in iPhones.

Handset sales rose 1% year-over-year to $6.18 billion, signaling that the smartphone market may be recovering after a few years of post-covid slumping. Qualcomm called out strong demand for “premium tier” smartphones that require the most advanced chips, especially in China. Qualcomm said that revenue from Chinese phone makers increased 40% on an annual basis during the quarter.

Qualcomm calls the phones that use its best chips “AI-powered smartphones,” citing features such as generative email completion, live translation, and virtual assistants that use the chips specialized “NPU” AI section. One such phone is Samsung’s Galaxy S24 Ultra, which launched earlier this year.

“As AI expands rapidly from the cloud to devices, we are extremely well positioned to capitalize on this growth opportunity,” Qualcomm CEO Cristiano Amon said on an earnings call with analysts.

The company’s automotive business, which sells chips to automakers, also showed signs of growth, rising 35% on an annual basis to $603 million. Qualcomm said it expected consecutive double-digit percentage growth in the division in the current quarter. The company’s so-called “Internet of Things” business — comprised of lower-cost chips and chips for virtual reality — contracted 11% year-over-year to $1.24 billion.

Those three business lines are reported together as QCT, the company’s chip business, which saw a 1% year-over-year sales increase to $8.03 billion. Qualcomm also highlighted

The company’s licensing business, QTL, in which it collects fees from companies that want to integrate 5G or cellular technology into their products, rose 2% on an annual basis to $1.32 billion.

Qualcomm said it paid $895 million in dividends and repurchased $731 million in shares during the quarter. Qualcomm raised its quarterly dividend to 85 cents from 80 cents previously.

Continue Reading

Trending